natriuretic-peptide--brain has been researched along with Neuroendocrine-Tumors* in 4 studies
2 review(s) available for natriuretic-peptide--brain and Neuroendocrine-Tumors
Article | Year |
---|---|
Carcinoid Heart Disease: A Review.
Carcinoid heart disease remains a major cause of morbidity and mortality among patients with carcinoid syndrome and metastatic neuroendocrine tumors. Screening of all patients with N-terminal pro-B-type natriuretic peptide and transthoracic echocardiography is critical for early detection, as early symptoms and signs have low sensitivity for the disease. Cardiac surgery, in appropriate cases, is the only definitive therapy for advanced carcinoid heart disease, and it improves patient symptoms and survival. Management of carcinoid heart disease is complex, and multidisciplinary assessment of cardiac status, hormonal syndrome, and tumor burden is critical in guiding optimal timing of surgery. Topics: Carcinoid Heart Disease; Cardiac Surgical Procedures; Humans; Natriuretic Peptide, Brain; Neuroendocrine Tumors; Peptide Fragments | 2018 |
GEP-NETs UPDATE: Secreting gastro-enteropancreatic neuroendocrine tumours and biomarkers.
Neuroendocrine tumours (NETs) are rare tumours with an annual incidence in the population in a range of 2-5 new cases per 100,000 inhabitants. NETs are widely variable in terms of anatomical location, hormone production, clinical behaviour and syndromes they can cause. This article reviews the many localizations and clinical presentations of NETs with a main focus on clinical biomarkers and their use in medical practice. Topics: Biomarkers; Chromogranin A; Humans; Immunohistochemistry; Intestinal Neoplasms; Natriuretic Peptide, Brain; Neuroendocrine Tumors; Organ Specificity; Pancreatic Neoplasms; Pancreatic Polypeptide; Peptide Fragments; Prognosis; Recombinant Proteins; Serotonin; Stomach Neoplasms | 2016 |
2 other study(ies) available for natriuretic-peptide--brain and Neuroendocrine-Tumors
Article | Year |
---|---|
Determination of the optimal echocardiographic scoring system to quantify carcinoid heart disease.
Carcinoid heart disease (CHD) is an important complication of metastatic neuroendocrine disease, requiring regular monitoring to enable intervention prior to right heart failure. We aimed to identify the most appropriate echocardiographic scoring systems for the quantitative assessment of CHD.. In this prospective study conducted between April and October 2012 in two European Neuroendocrine Tumor Society (ENETS) Centres of Excellence, patients with neuroendocrine tumours with liver metastases and/or carcinoid syndrome underwent transthoracic echocardiography and blood sampling for serum N-terminal pro-brain natriuretic peptide (NT-proBNP) and plasma 5-hydroxyindoleacetic acid (5-HIAA). Each patient was assessed according to six echocardiographic scoring systems. The individual scoring systems' feasibility, observer variability, sensitivity, specificity and correlation with the concentration biomarkers were determined.. 100 patients were included; 21% had echocardiographic evidence of CHD. All scores discriminated highly between those with/without CHD, with no single score performing significantly better than another. The severity, determined using all of the scoring systems, correlated with the concentration of both biomarkers, but the strongest correlations were seen between the Bhattacharyya score and serum NT-proBNP.. All scoring systems are comparable in terms of sensitivity and specificity for the detection of CHD. There is a variation in the feasibility of the scoring systems due to varying complexity of the score components. All scores correlate with NT-proBNP and plasma 5-HIAA. The Westberg score appears to be the most optimal scoring system for use in screening of CHD whereas the more complex scoring systems are more suited to the patient with established disease who may require surgical intervention. Topics: Aged; Aged, 80 and over; Biomarkers; Carcinoid Heart Disease; Echocardiography; Feasibility Studies; Female; Humans; Hydroxyindoleacetic Acid; Male; Middle Aged; Natriuretic Peptide, Brain; Neuroendocrine Tumors; Observer Variation; Peptide Fragments; Prospective Studies; Research Design; Retrospective Studies; Sensitivity and Specificity | 2014 |
Chromogranin-A and N-terminal pro-brain natriuretic peptide: an excellent pair of biomarkers for diagnostics in patients with neuroendocrine tumor.
For the last decade chromogranin-A (CgA) has been a well-established marker for neuroendocrine tumor (NET), and N-terminal pro-brain natriuretic peptide (NT-proBNP) has been a useful marker for left ventricular dysfunction. This study examined the diagnostic value of CgA and NT-proBNP for carcinoid heart disease (CHD), and their prognostic value for overall survival in NET patients.. Serum samples were obtained and cardiac ultrasound studies performed in 102 NET patients. The criterion for mild and severe CHD was tricuspid regurgitation stage I/II and III/IV, respectively. Proportional odds and Cox proportional hazards models were constructed respectively to identify the association between CHD and overall survival with patient characteristics and the two markers.. Severe CHD was found in 15 (15%) of 102 patients, 13 of whom had elevated NT-proBNP levels. In the univariate proportional odds model CHD was correlated with age (P = .007), CgA (P = .002), and NT-proBNP (P < .001), whereas in the multivariate model NT-proBNP and CgA were significantly associated with CHD (P < .001 and P = .01). In the univariate Cox models, age (P = .04), sex (P = .03), CgA (P = .003), and NT-proBNP (P = .04) were related to overall survival, and in the multivariate model CgA and NT-proBNP remained significantly related to overall survival (P = .002 and P = .04, respectively).. NT-proBNP and CgA are very important markers in the diagnosis of CHD in patients with NET. Furthermore, patients with elevated NT-proBNP in addition to elevated CgA levels showed worse overall survival than patients with elevated CgA alone. Topics: Aged; Biomarkers; Carcinoid Heart Disease; Chromogranin A; Female; Humans; Immunoradiometric Assay; Male; Middle Aged; Multivariate Analysis; Natriuretic Peptide, Brain; Neuroendocrine Tumors; Peptide Fragments; Predictive Value of Tests; Proportional Hazards Models; Sensitivity and Specificity; Survival Analysis | 2009 |